Pharmaceuticals

Discovery, development, regulation and marketing of the medications that are used in health care and the economics of the pharmaceutical industry.

Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents

Research Brief
Jan. 19, 2018

High out-of-pocket (OOP) costs may limit access to novel oral cancer medications. In a retrospective study, nearly one third of patients whose OOP costs were $100 to $500 and nearly half of patients whose OOP costs were more than $2,000 failed to pick up their new prescription for an oral cancer medication, compared to 10% of patients who were required to pay less than $10 at the time of purchase. Delays in picking up prescriptions were also more frequent among patients facing higher OOP costs. 

Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma

Dec. 12, 2017

Pengxiang (Alex) Li, Yu-Ning Wong, Jordan Jahnke, Amy R. Pettit, and Jalpa A. Doshi

In Cancer Medicine, Pengxiang (Alex) Li and colleagues, including Jalpa Doshi, explore whether high out-of-pocket costs limit access to oral therapies for Medicare patients newly diagnosed with metastatic renal cell carcinoma. Using 2011–2013 Medicare claims, the investigators identified 1,721 patients newly diagnosed with metastases in the liver, lung, or bone. They compared low-income Medicare Part D beneficiaries (who had low out-of-pocket costs due to...

Pharmaceutical Patent Citations and Value

Dec. 7, 2017

Discussions of drug pricing often link high prices with the need to promote innovation in the pharmaceutical industry. New technology can drive improved health outcomes, social welfare, and economic growth, but assigning value to specific innovations is technically difficult.

The Value of Value Frameworks

Oct. 26, 2017

“Value” is more than a buzzword. In response to rising costs, payers, physicians, and patients have turned to value assessment frameworks to inform treatment plans and design sustainable budgets. However, the usefulness and potential of these tools remain murky. LDI’s 50th anniversary symposium convened a panel to elucidate key questions for the future of value frameworks—what does value mean to different stakeholders in the health care system? How should payers, doctors, and patients appraise the value of the care they receive?

Abuse Deterrent Opioids: A Hard Sell

Sep. 25, 2017

One strategy to combat the opioid epidemic is to change the formulation of opioids to deter abuse. Reformulations can make opioids harder or less pleasant to inject, snort, or chew, thereby reducing common methods of abuse. Since 2010, the FDA has approved 10 opioid abuse deterrent formulations, which are considerably more expensive than regular brand opioids. The question is, do they work, and at what cost?

The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group

Jul. 5, 2017

Deverick J. Anderson, Timothy C. Jenkins, Scott R. Evans, Anthony D. Harris, Robert A. Weinstein, Pranita D. Tamma, Jennifer H. Han, Ritu Banerjee, Robin Patel, Theoklis Zaoutis, Ebbing Lautenbach

In Clinical Infectious Diseases, Deverick Anderson and colleagues, including Jennifer Han and Ebbing Lautenbach, describe the activities of the Antibacterial Resistance Leadership Group (ARLG) in the area of antibacterial stewardship. Antibacterial resistance is increasing globally and has been recognized as a major public health threat. Antibacterial stewardship is the coordinated effort to improve the appropriate use of antibiotics with the aim to decrease selective pressure for multidrug-resistant organisms in order to preserve the utility of antibacterial agents. To date, the...

Conflict of Interest for Patient-Advocacy Organizations

Jun. 29, 2017

Matthew S. McCoy, Micahel Carniol, Katherine Chockley, John W. Urwin, Ezekiel J. Emanuel, and Harald Schmidt

In the New England Journal of Medicine, Matthew McCoy and colleagues, including Ezekiel Emanuel, examine conflicts of interest arising from the presence of industry executives on the boards of patient-advocacy organizations. Previous research has raised concern that the presence of industry leaders on the boards of these non-profit organizations may lead to advocacy for questionable reforms that do not always benefit the organizations’ constituents. The authors analyzed tax records, annual reports, and websites of 104 of the largest U.S patient-advocacy organizations to understand...

Pages